Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system

ConclusionsClinical trials of inotersen and patisiran showed that these agents were able to halt the progression of the disease, with some patients even reducing the burden of polyneuropathy, and improving qualify of life. The information on their impact on autonomic parameters is limited, warranting further dedicated studies.
Source: Clinical Autonomic Research - Category: Research Source Type: research